drugset / Trial / NCT00632840
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
Phase 4
Completed
11 enrolled
The University of Western Australia
National Heart Foundation, Australia · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.
Timeline
- Start
- 2001-06
- Primary completion
- 2002-12
- Completion
- 2007-12
Publications
- Chan DC, Watts GF, Ooi EM, Rye KA, Ji J, Johnson AG, Barrett PH. Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care. 2009 Nov;32(11):2111-3. doi: 10.2337/dc09-0519. Epub 2009 Aug 3.
- Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009 Mar;94(3):989-97. doi: 10.1210/jc.2008-1457. Epub 2008 Dec 30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 40 mg | — |
| Comparator | Fenofibrate | Small molecule | 200 mg | — |